National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
HPV (Human Papillomavirus) Vaccines for Cervical Cancer
    Posted: 06/08/2006    Updated: 11/07/2007

Links to NCI Materials

NCI-supported Research about HPV

HPV Clinical Trial Results

Links to Other Federal Government Materials

Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

NCI Highlights
The Cancer Genome Atlas Reports Brain Tumors Study

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Related Pages
Cancer Stat Fact Sheet: Cancer of the Cervix Uteri
Overview of frequently requested cancer statistics such as incidence, mortality, and survival rates.
Links to NCI Materials

On June 8, 2006, the U.S. Food and Drug Administration (FDA) approved the use of a new vaccine to prevent infection from four types of the human papillomavirus (HPV). Two of the HPV types targeted by the vaccine (HPV-16 and HPV-18) are responsible for about 70 percent of the cases of cervical cancer worldwide. The other two HPV types (HPV-6 and HPV-11) cause approximately 90 percent of the cases of genital warts. The vaccine, made by Merck & Co., Inc., is based on laboratory research and technology developed at the National Cancer Institute (NCI). NCI played a pivotal role in what holds promise to be a major public health success story. NCI continues to conduct research on HPV and cervical cancer.

The links on this page and in the next sections provide more information about HPV, vaccines, and cervical cancer.

For answers to your questions about HPV and cervical cancer, contact an information specialist with NCI's Cancer Information Service (CIS) by calling 1-800-4-CANCER or by using NCI's LiveHelp text chat service.

About HPV Vaccines
FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus
Announcement of the Food and Drug Administration approval of Gardasil, the first vaccine developed to prevent cervical cancer, precancerous genital lesions and genital warts due to human papillomavirus (HPV) types 6, 11, 16 and 18.

Statement from the National Cancer Institute on FDA Approval of the HPV Vaccine
Nearly two decades ago, researchers at the National Cancer Institute (NCI) and other institutions began searching for the underlying causes of cervical cancer. That scientific quest led to today's approval by the Food and Drug Administration of the vaccine Gardasil™, which protects against infection from the two types of human papillomavirus (HPV) that cause the majority of cervical cancers worldwide.

Human Papillomavirus Vaccines: Questions and Answers
A fact sheet about human papillomavirus (HPV) vaccines for the prevention of infection with certain types of HPV, which is the major cause of cervical cancer. National Cancer Institute Fact Sheet 3.79

Understanding Cancer Series: HPV Vaccine
This tutorial, part of the Understanding Cancer Series, discusses human papillomavirus (HPV) infection and the use of a vaccine to protect against future HPV infection.

About HPV
Human Papillomaviruses and Cancer: Questions and Answers
A fact sheet about the link between human papillomavirus (HPV) infection and cancer. National Cancer Institute Fact Sheet 3.20

Study Estimates Overall HPV Prevalence in U.S. Women
Data published in the February 28, 2007, Journal of the American Medical Association provide the first national estimate of the prevalence of human papillomavirus (HPV) infection among women in the United States.

HPV a Risk Factor for Oropharyngeal Cancer
An epidemiological study led by researchers from Johns Hopkins University implicates human papillomavirus (HPV) exposure and infection as strong risk factors for oropharyngeal cancer, according to the May 10, 2007, New England Journal of Medicine.

A Primer on HPV
A brief guide to human papillomavirus (HPV), including transmission, incidence, treatment, and its connection to genital warts and cancer.
General Information about Cancer Vaccines and Cervical Cancer
Cancer Vaccine Fact Sheet
Cancer vaccines are intended either to treat existing cancers (therapeutic vaccines) or to prevent the development of cancer (prophylactic vaccines).

Treating and Preventing Cancer with Vaccines
Cancer vaccines are being tested in clinical trials to see if they can help to prevent or treat a wide variety of cancer types. This feature provides an introduction to cancer vaccines - how they work and why researchers think they're promising.

NCI Pursues Vaccines to Prevent and Treat Cancer
In this issue, BenchMarks examines prevention and treatment cancer vaccines that are currently in development at NCI and other cancer centers.

Cervical Cancer Home Page
NCI's gateway for information about cervical cancer.

Cervical Cancer - NCI Office of Women's Health
Collection of links to NCI information about research on cervical cancer, including statistics, descriptions of research projects, and reports of progress in cervical cancer research.

Next Section >

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health